A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy
详细信息 查看全文
- 作者：Tzu-I Chaoa ; 1 ; Wei-Tien Taia ; b ; 1 ; Man-Hsin Hungc ; d ; 1 ; Ming-Hsien Tsaia ; Min-Hsuan Chena ; Mao-Ju Changa ; Chung-Wai Shiaue ; Kuen-Feng Chena ; b ; kfchen1970@ntu.edu.tw" class="auth_mail" title="E-mail the corresponding author
- 关键词：HCC ; hepatocellular carcinoma ; SHP-1 ; Src homology region 2 domain containing phosphatase 1 ; STAT3 ; signal transducer and activator of transcription 3 ; p-STAT3 ; phosphorylated STAT3 ; Raf ; rapidly accelerated fibrosarcoma ; VEGFR ; vascular endothelial growth factor receptor ; PDGFR ; platelet-derived growth factor receptor ; PTP ; protein tyrosine phosphatase ; SH2 ; Src homology region 2 ; DMSO ; dimethyl sulfoxide ; DMEM ; Dulbecco's modified Eagles' medium ; PARP ; Poly (ADP-ribose) polymerase ; Mcl-1 ; myel
- 刊名：Cancer Letters
- 出版年：2016
- 出版时间：28 February 2016
- 年：2016
- 卷：371
- 期：2
- 页码：205-213
- 全文大小：2717 K
文摘
- •
We employed two SHP-1 agonists, sorafenib and SC-43, for HCC treatment.
- •
The synergistic action of sorafenib and SC-43 further enhanced HCC apoptosis.
- •
Diminished STAT3-related signals and increased cell death were observed.
- •
The add-on strategy resulted in smaller tumor size in the subcutaneous model.
- •
The novel combination contributed to 100% survival in the orthotopic HCC model.